Jasper Therapeutics Inc. has released a corporate presentation detailing the clinical progress and therapeutic strategy of their investigational drug, briquilimab. The presentation highlights briquilimab's potential in treating mast cell-driven diseases through KIT inhibition, which has shown to significantly deplete mast cells for durable and well-tolerated disease control. Clinical studies, such as BEACON and SPOTLIGHT, demonstrate briquilimab's rapid onset and high response rates in conditions like chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU). The ongoing ETESIAN study for asthma and evaluations in other mast cell-mediated diseases further emphasize the drug's potential franchise expansion. Briquilimab, not yet approved for any indication, continues to show promise in various clinical studies. You can access the full presentation through the link below.